Abstract
Purpose: Communication about complementary and alternative medicine (CAM) between cancer patients and health professionals rarely takes place. This article reports on an intervention study that aimed to support communication about the use and effects of CAM between cancer patients and care providers. Methods: The intervention consisted of the use of evidence-based information material (website; leaflet) about the effects of CAM for cancer. Focus groups with cancer patients, relatives, nurses and doctors (n = 50) determined the preferred content and format of materials and evaluated the intervention. The information material was informed by a related systematic metareview of literature. A survey identified patient participants’ CAM use, information sources, and the extent of communication about CAM before and after the intervention. Results: No significant impact of the intervention on communication about CAM for cancer patients, patients’ CAM use or sources of information was identified. Health professionals disseminated the leaflet only in response to patients raising the topic; the website was not accessed during consultations. The intervention and information materials were well received. Conclusion: Cancer patients and care providers wish to improve communication about CAM. Nevertheless, patients and professionals wait for the other to broach the subject of CAM. This reflects a “culture of waiting.”
References
1.
Nissen
N
, Schunder-Tatzber
S
, Weidenhammer
W
, Johannessen
H
. What attitudes and needs do citizens in Europe have in relation to complementary and alternative medicine?
Forsch Komplement Med
. 2012
;19
(s2
Suppl 2
):9
–17
.
[PubMed]
1661-41192.
Frenkel
M
, Ben-Arye
E
, Cohen
L
. Communication in cancer care: discussing complementary and alternative medicine
. Integr Cancer Ther
. 2010
Jun
;9
(2
):177
–85
.
[PubMed]
1534-73543.
Rausch
SM
, Winegardner
F
, Kruk
KM
, Phatak
V
, Wahner-Roedler
DL
, Bauer
B
, et al Complementary and alternative medicine: use and disclosure in radiation oncology community practice
. Support Care Cancer
. 2011
Apr
;19
(4
):521
–9
.
[PubMed]
0941-43554.
Kræftens Bekæmpelse
. Kræftpatienters behov og oplevelser med sundhedsvæsenet under udredning og behandling. Kræftens Bekæmpelses Barometerundersøgelse
. København
: Kræftens Bekæmpelse
; 2017
. p. 132
.5.
Pihlak
R
, Liivand
R
, Trelin
O
, Neissar
H
, Peterson
I
, Kivistik
S
, et al Complementary medicine use among cancer patients receiving radiotherapy and chemotherapy: methods, sources of information and the need for counselling
. Eur J Cancer Care (Engl)
. 2014
Mar
;23
(2
):249
–54
.
[PubMed]
0961-54236.
Wode
K
, Henriksson
R
, Sharp
L
, Stoltenberg
A
, Hök Nordberg
J
. Cancer patients’ use of complementary and alternative medicine in Sweden: a cross-sectional study
. BMC Complement Altern Med
. 2019
Mar
;19
(1
):62
.
[PubMed]
1472-68827.
Klein
GE
, Guethlin
C
. Information and Training Needs Regarding Complementary and Alternative Medicine: A Cross-sectional Study of Cancer Care Providers in Germany
. Integr Cancer Ther
. 2018
Jun
;17
(2
):380
–7
.
[PubMed]
1534-73548.
Dahlhaus
A
, Siebenhofer
A
, Guethlin
C
. Complementary medicine for cancer patients in general practice: qualitative interviews with german general practitioners
. Forsch Komplementmed
. 2015
;22
(1
):36
–41
.
[PubMed]
1661-41279.
Tovey
P
, Broom
A
. Oncologists’ and specialist cancer nurses’ approaches to complementary and alternative medicine and their impact on patient action
. Soc Sci Med
. 2007
Jun
;64
(12
):2550
–64
.
[PubMed]
0277-953610.
Stub
T
, Quandt
SA
, Arcury
TA
, Sandberg
JC
, Kristoffersen
AE
. Attitudes and knowledge about direct and indirect risks among conventional and complementary health care providers in cancer care
. BMC Complement Altern Med
. 2018
Jan
;18
(1
):44
.
[PubMed]
1472-688211.
Lee
RT
, Barbo
A
, Lopez
G
, Melhem-Bertrandt
A
, Lin
H
, Olopade
OI
, et al National survey of US oncologists’ knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer
. J Clin Oncol
. 2014
Dec
;32
(36
):4095
–101
.
[PubMed]
0732-183X12.
Corina
G
, Christine
H
, Klein
G
. Oncologists’ experiences of discussing complementary and alternative treatment options with their cancer patients. A qualitative analysis
. Support Care Cancer
. 2016
Sep
;24
(9
):3857
–62
.
[PubMed]
0941-435513.
Mao
JJ
, Palmer
CS
, Healy
KE
, Desai
K
, Amsterdam
J
. Complementary and alternative medicine use among cancer survivors: a population-based study
. J Cancer Surviv
. 2011
Mar
;5
(1
):8
–17
.
[PubMed]
1932-225914.
Nissen
N
, Lunde
A
, Pedersen
CG
, Johannessen
H
. The use of complementary and alternative medicine after the completion of hospital treatment for colorectal cancer: findings from a questionnaire study in Denmark
. BMC Complement Altern Med
. 2014
Oct
;14
(1
):388
.
[PubMed]
1472-688215.
Anker
N
. Kræftpatienters brug af alternativ behandling. hovedresultater. En undersøgelse blandt brugerne af Kræftens Bekæmpelses telefonrådgivning: Kræftlinien
. København
: Kræftens Bekæmpelse
; 2006
.16.
Davis
EL
, Oh
B
, Butow
PN
, Mullan
BA
, Clarke
S
. Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review
. Oncologist
. 2012
;17
(11
):1475
–81
.
[PubMed]
1083-715917.
Molassiotis
A
, Fernández-Ortega
P
, Pud
D
, Ozden
G
, Scott
JA
, Panteli
V
, et al Use of complementary and alternative medicine in cancer patients: a European survey
. Ann Oncol
. 2005
Apr
;16
(4
):655
–63
.
[PubMed]
0923-753418.
Damkier
A
. Kræftpatienters brug af alternativ behandling
. Odense
: Syddansk Universitet
; 2000
.19.
Verhoef
MJ
, Balneaves
LG
, Boon
HS
, Vroegindewey
A
. Reasons for and characteristics associated with complementary and alternative medicine use among adult cancer patients: a systematic review
. Integr Cancer Ther
. 2005
Dec
;4
(4
):274
–86
.
[PubMed]
1534-735420.
Nissen
N
, Weidenhammer
W
, Schunder-Tatzber
S
, Johannessen
H
. What attitudes and needs do citizens in Europe have in relation to information about CAM?
Forsch Komplementarmed
. 2013
;20
supplement 1
:11
.1021-709621.
Nissen
N
, Weidenhammer
W
, Schunder-Tatzber
S
, Johannessen
H
. Public health ethics for complementary and alternative medicine
. Eur J Integr Med
. 2013
;5
(1
):62
–7
. 1876-382022.
Shea
BJ
, Grimshaw
JM
, Wells
GA
, Boers
M
, Andersson
N
, Hamel
C
, et al Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews
. BMC Med Res Methodol
. 2007
Feb
;7
(1
):10
.
[PubMed]
1471-228823.
Verhoef
MJ
, Boon
HS
, Page
SA
. Talking to cancer patients about complementary therapies: is it the physician’s responsibility?
Curr Oncol
. 2008
Aug
;15
(0
Suppl 2
):s88
–93
.
[PubMed]
1198-005224.
Brophy
E
. Does a doctor have a duty to provide information and advice about complementary and alternative medicine?
J Law Med
. 2003
Feb
;10
(3
):271
–84
.
[PubMed]
1320-159X25.
Balneaves
LG
, Truant
TL
, Verhoef
MJ
, Ross
B
, Porcino
AJ
, Wong
M
, et al The Complementary Medicine Education and Outcomes (CAMEO) program: a foundation for patient and health professional education and decision support programs
. Patient Educ Couns
. 2012
Dec
;89
(3
):461
–6
.
[PubMed]
0738-3991© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
